Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Cash Flows

v2.4.0.6
Consolidated Statements of Cash Flows (USD $)
In Thousands, unless otherwise specified
 12 Months Ended
Dec. 31, 2011
Dec. 31, 2010
Cash Flows From Operating Activities    
Net loss $ (11,914) $ (6,814)
Adjustments to reconcile net income to net cash    
Depreciation and amortization 3,046 1,829
Realignment accrual accretion 161 147
Deferred income taxes, net 0 5
Provision for bad debt, net 58 30
Reversal of contingent consideration accrual (1,557) 0
Non-cash loss on sale of Pharmakon 6,868 0
Stock-based compensation 1,936 1,494
Non-cash facilities realignment 0 575
Other losses and expenses, net 0 16
Other changes in assets and liabilities:    
Decrease in accounts receivable 1,397 2,095
Decrease in unbilled costs 770 711
Decrease in income tax receivable 0 3,298
(Increase) decrease in other current assets (1,797) 327
Decrease in other long-term assets 2,617 0
Increase in accounts payable 873 522
Increase in unearned contract revenue 2,465 2,625
(Decrease) increase in accrued salaries and bonus (2,381) 4,512
Increase in accrued liabilities 1,817 5,142
Decrease in long-term liabilities (2,374) (162)
Net cash provided by operating activities 1,985 16,352
Cash Flows From Investing Activities    
Cash paid for acquisition, net of cash acquired 0 (23,912)
Purchase of property and equipment (343) (2,130)
Net cash used in investing activities (343) (26,042)
Cash Flows From Financing Activities    
Cash paid for repurchase of restricted shares (16) (62)
Payments for Repurchase of Common Stock (16) (62)
Net cash used in financing activities (16) (62)
Net increase (decrease) in cash and cash equivalents 1,626 (9,752)
Cash and cash equivalents – beginning 62,711 72,463
Cash and cash equivalents – ending 64,337 62,711
Cash paid for taxes 37 86
Retained Earnings [Member]
    
Cash Flows From Operating Activities    
Net loss $ (11,914) $ (6,814)